Kodiak's stock doubles as resurrected eye disease drug matches Eylea in phase 3

Kodiak Sciences' eye disease drug candidates tarcocimab and tabirafusp matched the efficacy of Regeneron's Eylea in a phase 3 trial for wet age-related macular degeneration, leading to a planned FDA approval filing later this year. Kodiak's stock surged as the drugs demonstrated rapid vision improvements and longer dosing intervals, despite competition from biosimilars and branded rivals.

This Wire brief sits within Fusion42's coverage of Biotech.